CRITICAL REVIEW ON BOMBAX CEIBA, ALOE VERA AND XIMENIA AMERICANA

Therapeutic plants are extensively increased in scenery with their efficient therapeutic properties. India has the greater natural ecosystem from past two decades, near has been a marvelous augment in the applications of natural medicines; though there is still a noteworthy deficiency in the research of medicinal plants and it has the great resources of medicinal plants which are noteworthy to human beings in many ways. The medicinal plants such as Bombax ceiba, Aloe vera and Ximenia Americana are well known to cure several diseases therefore used in different Ayurvedic preparation somehow they are lagging behind in the list of medicinal plants for their applications in drug preparations. These plants has great ethnopharmaceutical and pharmacological properties with therapeutic applications therefore present review gives different aspects of Bombax ceiba, Aloe vera and Ximenia americana and may help to create awareness in society.                    Peer Review History: Received 25 February 2020; Revised 16 April; Accepted 7 May, Available online 15 May 2020 Academic Editor: Dr. Ali Abdullah Al-yahawi, Al-Razi university, Department of Pharmacy, Yemen, [email protected] UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency. Received file:                Reviewer's Comments: Average Peer review marks at initial stage: 5.0/10 Average Peer review marks at publication stage: 7.0/10 Reviewer(s) detail: Ahmad Najib, Universitas Muslim Indonesia, Makassar, Indonesia, [email protected] Dr. Mahmut Yıldıztekin, Muğla Sıtkı Koçman University, Turkey, [email protected] Similar Articles: A STUDY ON DIFFERENT PLANTS OF APOCYNACEAE FAMILY AND THEIR MEDICINAL USES A REVIEW ON MEDICINAL USES OF DIFFERENT PLANTS OF EUPHORBIACEAE FAMIL

Commentary on “Why am I still in hospital? Evaluation of delayed discharges from two learning disability assessment and treatment units in England”

Purpose This commentary explores the challenges and themes enumerated by the associated article “Why am I still in hospital? Evaluation of delayed discharges from two learning disability assessment and treatment units in England”. This commentary broadens and outlines the research’s background, premise and potential impact. This paper aims to critically examine the evidence on this subject. Design/methodology/approach This commentary considers the attitudes to inpatient care for people with learning disabilities in the past decade and outlines a possible compact for the future. Findings Contrary to popular and emotive beliefs that using specialist inpatient psychiatric settings for people with learning disabilities is universally a poor practice, there are defined occasions when such settings are needed and imperative in the clinical pathway. If people with learning disabilities can access inpatient settings at the right time for the right reason, psychiatric outcomes could be improved. Timely discharge is imperative and currently lacking due to a lack of suitable engagement mechanisms between inpatient settings and the community. Thus, evidence-based outcome tools are essential to facilitate appropriate discharge. Originality/value There is an ongoing debate on the value and utility of specialist inpatient psychiatric units for people with learning disabilities. This commentary provides a balanced, evidence-based insight into this discussion. </jats:sec

ANCIENT METHODS OF RESEARCH IN AYURVEDA

Ayurveda is the Upaveda of Atharvaveda, the ancient literature which gave us the knowledge of healthier life. The absolute aim of Ayurveda is to maintain the health of a healthier person and diagnose and treat the diseased person. Ayurveda has the ability to treat many chronic diseases that are untreatable in modern medicine, it has got some very preventive and curative tools to treat the diseases, but unfortunately, due to the lack of scientific validation in various concepts, this precious gift from our ancestors is trailing. In a nutshell, Ayurveda gives human a healthy life with proven methods of medical treatment. The ancient methods of treatment are very effective and relevant in present time also. Hence, evidence-based research is highly needed for global recognition and acceptance of Ayurveda, which needs further advancements in the research methodology

PRODUCTION OF CHITINASE BY SOLID STATE FERMENTATION

The goal of this research project is to find out the novel Chitinases producing bacteria. The soil samples were collected from the Miraj and Osmanabad fish market and enriched in MS medium containing chitin as the sole source of carbon. 10 Bacterial species were isolated from soil samples by serial dilution technique and spread plate technique on nutrient agar and potato dextrose agar medium. The isolated bacterial species were screened for Chitinase production by primary screening on Colloidal chitin agar medium. Those Bacteria gives highest Chitinase hydrolysis zone used for Chitinase production by Solid State fermentation (SSF). The extracted Chitinase enzyme further used for Chitinase activity by DNS method in that highest Chitinase activity was 11.46µg/ml/min. on 11th day of fermentation

Valproate MHRA guidance: limitations and opportunities

Recent publication of the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has strengthened the regulatory measures for valproate medicines. It highlights the importance of making women of childbearing age with epilepsy aware of the teratogenic risks of valproate and encourages the withdrawal of it from those currently prescribed. While a significant directive, it raises concerns of not having considered the impact on special populations such as women with Intellectual Disability (ID). While it is important that women with ID are not excluded from such safety initiatives, due caution needs to be taken on a case by case basis preferably, to ensure their best interests are central to the decision making. Many women with moderate to profound ID cannot have informed consented sexual relationships not to mention cognitive incapability to make informed choices on medication suitability. These women are at potential risk of having their epilepsy control undermined due to the MHRA directives. Around 30% of people with moderate to profound ID have seizures of which 60% are considered treatment resistant. In this vulnerable population changes to medication without clear clinical and social insights could lead to increased harm levels. This paper enumerates the challenges of application of the new directive to these special populations and proposes a pathway based on individual cognitive ability to provide informed consent to facilitate the continuation or removal of valproate. It is important not to lose sight of individual circumstances and the importance of working collaboratively toward providing person center care

A case of phenobarbitone induced Stevens-Johnson syndrome-toxic epidermal necrolysis along with its causality assessment

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse drug reaction, which are mainly caused by drugs; and these are usually associated with high degree of morbidity and mortality. They are characterized by mucocutaneous tenderness and typically haemorrhagic erosions, erythema and more or less severe epidermal detachment as blisters and areas of denuded skin.  High risk drugs for the development of SJS-TEN include phenobarbitone, phenytoin, carbamazepine, lamotrigine, nevirapine, NSAIDs, allopurinol, and cotrimoxazole. A 33 years old female patient came to skin and venereal diseases (VD) outpatient department (OPD) with complaints of painful skin lesions. She was apparently symptom free 15 days back. Then she took tablet phenobarbitone 60 mg, BD as her anti-epileptic treatment. After 12-13 days of taking the drug, she developed erythematous papules associated with itching over her both forearm, face, chest, abdomen, back and lower limbs bilaterally which rapidly progressed to fluid-filled blisters that ruptured to form painful erosions and desquamation of skin all over the body. The patient was managed by withdrawal of phenobarbitone and conservatively, and the patient recovered successfully. The causality of phenobarbitone in this reaction was “probable” as per Naranjo scale. Seriousness of the reaction was “prolonged hospitalization”. Phenobarbitone is one of the most common causative agents of SJS and TEN. The main stay of treatment is immediate withdrawal of causative agent along with supportive care

Challenges and pitfalls of antipsychotic prescribing in people with learning disability

No abstract available

Sudden unexpected death in epilepsy (SUDEP): Development of a safety checklist

AbstractPurposeThe incidence of sudden death appears to be 20 times higher in patients with epilepsy compared with the general population. Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP), is still underestimated by healthcare professionals and this may reflect the mistaken belief that epilepsy is a benign condition. The risk of death associated with epilepsy appeared rarely to have been discussed with patients or their families. It appears the decision to discuss SUDEP and also to peg SUDEP risk is arbitrary and clinical. Unfortunately there is no structured evidenced mechanism at present to represent person centered risk of SUDEP and there is currently no easy manner or template to have this discussion with the family and the patient.MethodsWe conducted a detailed literature review in Medline, Embase and Psychinfo databases to extract the common risk factors as evidenced from literature till date. Research into risk factors has identified a number of risk factors for SUDEP, some of which are potentially modifiable.ResultsBased on the literature review, we believe that the ascertained risk factors could be employed in clinical practice as a checklist to reduce an individual patient's risk of SUDEP. The SUDEP safety checklist may be of practical use in reducing risks in some individuals and is definitely of use in helping communication.ConclusionsAn evidence based checklist identifying the major risk factors can help both clinicians and patients to focus on minimizing certain risk factors and promote safety by focusing on the modifiable factors and guide treatment. It can be a tool to open a person centered discussion with patients and to outline how individual behaviors could impact on risk